No abstract available.
Drug Therapy* ; Humans ; Immunotherapy*

No abstract available.
Headache*

No abstract available.
Arm* ; Busan* ; Child* ; Humans

No abstract available.
Biliary Tract*

The skin is the most visible and easily accessible organ of the body. Therefore, as a readily available indicator, it can give a clue to many underlying systemic diseases ; it has great diagnostic implications, serving as a window to the diseases affecting the internal organs. Recognition of dermatological manifestations of systemic diseases is practically important for all practicing clinicians. In many instances, the recognition of the skin signs of systemic diseases should minimize the cost of diagnostic testing. Generally, skin symptoms are quite commonly associated with systemic disease. Various skin manifestations have been observed in patients with either benign of malignant systemic diseases, and they often give a clue to or confirm the underlying diseases. This lecture summarizes the cutaneous manifestations and specific skin signs that help to differential diagnoses of systemic diseases.
Diagnosis, Differential ; Diagnostic Tests, Routine ; Humans ; Skin ; Skin Manifestations

Bioequivalence is defined as the absence of a significant difference in the rate and extent to which the active ingredient or active moiety in pharmaceutical equivalents or pharmaceutical alternatives becomes available at the site of drug action when administered at the same molar dose under similar experimental conditions in either a single dose or multiple doses in an appropriately designed study. If a drug is to be bioequivalent to the reference drug, the confidence interval for both pharmacokinetic parameters, AUC(area under the plasma concentration-time curve) and Cmax(maximal plasma concentration), must be entirely within the 80% to 125% of those of the reference drug. Underlying the concept of bioequivalence is the thesis that, if a drug product contains a drug substance that is chemically identical and is delivered to the site of action at the same rate and extent as another drug product, then it is equivalent and can be substituted for that drug product. The primary concern from the regulatory point of view is the protection of the patient against approval of products that are not bioequivalent. In this paper the general concept and the practical significance of the bioequivalence is described. The recently revised Korean guideline for bioequivalence test is also discussed.
Drug Substitution ; Humans ; Molar ; Plasma ; Therapeutic Equivalency*

No abstract available.

No abstract available.
Headache*

No abstract available.
Complementary Therapies*

No abstract available.
Sexually Transmitted Diseases*